Janus Henderson Group
IBRX icon

Janus Henderson Group’s ImmunityBio IBRX Stock Holding History

Janus Henderson Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
157,439
+38,700
+33% +$265K ﹤0.01% 1616
2025
Q4 		$235K Hold
118,739
– – ﹤0.01% 2302
2025
Q3 		$292K Hold
118,739
– – ﹤0.01% 2216
2025
Q2 		$313K Buy
118,739
+58,899
+98% +$158K ﹤0.01% 2151
2025
Q1 		$187K Hold
59,840
– – ﹤0.01% 2377
2024
Q4 		$153K Hold
59,840
– – ﹤0.01% 2473
2024
Q3 		$222K Hold
59,840
– – ﹤0.01% 2399
2024
Q2 		$377K Sell
59,840
-686
-1% -$4.52K ﹤0.01% 2103
2024
Q1 		$324K Buy
60,526
+11
+0% +$50 ﹤0.01% 2200
2023
Q4 		$303K Sell
60,515
-1
-0% -$3 ﹤0.01% 2235
2023
Q3 		$101K Buy
60,516
+34
+0.1% +$68 ﹤0.01% 2518
2023
Q2 		$168K Buy
60,482
+157
+0.3% +$444 ﹤0.01% 2496
2023
Q1 		$109K Buy
60,325
+28,703
+91% +$89.2K ﹤0.01% 2612
2022
Q4 		$160K Sell
31,622
-31,622
-50% -$174K ﹤0.01% 2237
2022
Q3 		$314K Buy
63,244
+29,774
+89% +$136K ﹤0.01% 2194
2022
Q2 		$125K Buy
+33,470
New +$134K ﹤0.01% 2434

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Janus Henderson Group's IBRX Position: Q1 2026 in Review

Janus Henderson Group increased its ImmunityBio (IBRX) stake by 33% in Q1 2026, buying an estimated $265K and bringing the position to 157,439 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Janus Henderson Group first reported a position in IBRX in Q2 2022 and has held it in 16 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Janus Henderson Group held 157,439 shares of ImmunityBio worth $1.2M as of Q1 2026.
  • Janus Henderson Group bought 38,700 ImmunityBio shares in Q1 2026, an estimated $265K.
  • ImmunityBio made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1616 holding.
  • Janus Henderson Group first reported a position in ImmunityBio in Q2 2022 and has held it in 16 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.